Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, January 31, 2022
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
Sun, January 30, 2022
[ Sun, Jan 30th 2022
] - WOPRAI
[ Sun, Jan 30th 2022
] - WOPRAI
[ Sun, Jan 30th 2022
] - WOPRAI
[ Sun, Jan 30th 2022
] - WOPRAI
Fri, January 28, 2022
[ Fri, Jan 28th 2022
] - WOPRAI
[ Fri, Jan 28th 2022
] - WOPRAI
[ Fri, Jan 28th 2022
] - WOPRAI
[ Fri, Jan 28th 2022
] - WOPRAI
[ Fri, Jan 28th 2022
] - WOPRAI
[ Fri, Jan 28th 2022
] - WOPRAI
[ Fri, Jan 28th 2022
] - WOPRAI
Mani Foroohar Maintained (ARWR) at Hold with Increased Target to $46 on, Jan 28th, 2022
Mani Foroohar of SVB Leerink, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold with Increased Target from $45 to $46 on, Jan 28th, 2022.
Mani has made no other calls on ARWR in the last 4 months.
There is 1 other peer that has a rating on ARWR. Out of the 1 peers that are also analyzing ARWR, 0 agree with Mani's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mani
- Madhu Kumar of "Goldman Sachs" Upgraded from Hold to Strong Buy on, Wednesday, January 19th, 2022
